LYNBROOK, N.Y., June 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC BB BSTC.OB-News) today announced that it sold an aggregate of 100,000 unregistered shares of its common stock priced at $15 per share for aggregate proceeds to BioSpecifics of $1,500,000. The shares were purchased by certain private investors on June 9, 2008. The shares were sold in a company managed PIPE transaction at a premium over the market price.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed and licensed injectable collagenase for three clinical
indications. It has a development and licensing agreement with Auxilium
Pharmaceuticals, Inc. for clinical indications in Dupuytren's disease,
Peyronie's disease and frozen shoulder (adhesive capsulitis).
BioSpecifics' main website is at
its Dupuytren's Disease patient discussion forum at
and its Peyronie's Disease patient discussion forum at
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2008 PR Newswire.
All rights reserved